USANA Health Sciences Q2 Earnings Call Highlights
USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.
How this was made
The 30-second read
Why it matters
The key trading takeaway is the combination of (1) a non-cash goodwill impairment tied to Hiya, (2) quantified top-line and margin pressure, and (3) an elevated expected tax rate for the rest of the year, partially offset by strong cash and working-capital management.
Market read
Investors get quantified guidance pressure and impairment details from USANA’s Q2 call, which can drive near-term estimate revisions and sentiment.
What to watch
The packaging issue at Rise is described as resolved and the company expects >4,000 retail doors by end-2026, which may offset some near-term revenue pressure if sell-through improves.
Background
USANA’s Q2 call covered product expansion (Glow), Hiya marketing headwinds from Meta ad changes, and a Rise packaging disruption, alongside a goodwill impairment and outlook reduction.
Ticker impact
USANA disclosed a preliminary $29M goodwill impairment tied to its Hiya reporting unit and reduced its outlook, citing $30M to $40M top-line pressure.
Likely bearish bias for the stock into the next earnings cycle as investors reprice the Hiya/Rise growth and margin outlook.
The article provides concrete charges ($29M impairment, $9M tax expense) and quantified guidance pressure ($30M to $40M revenue, $4M to $5M margin), which are direct inputs to valuation and near-term expectations.
Market effects
Highlights execution and marketing-cost sensitivity in health and wellness brands, particularly for subscription-to-retail transitions.
No specific regional macro impact beyond international expansion commentary.
Limited global spillover; mostly company-specific guidance and impairment details.
Counterpoint
USANA emphasized financial flexibility (cash, no debt, positive free cash flow) and said the impairment does not change commitment to Hiya, which could limit downside if execution stabilizes.
Key entities
- companyUSANA Health Sciences
Disclosed a $29M preliminary goodwill impairment related to Hiya, reported charges, and reduced outlook citing revenue and margin pressure.
- brandHiya
USANA children’s health and wellness brand; subscriber growth pressured by higher customer acquisition costs and Meta ad platform changes.
- brandRise Wellness
Encountered a packaging issue that disrupted commercial execution; management says it is resolved.
